Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency
International Journal of Nanomedicine · 2025-03 · Volume 20 · 3269-3301
DOI: 10.2147/ijn.s504644 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025-03. Verfasst von Giulia Della Pelle und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department for Nanostructured Materials, Jožef Stefan Institute, Ljubljana, 1000, Slovenia. Hauptthemen laut MEDLINE: RNA, Small Interfering, Erythrocyte Membrane, Melanoma, Experimental, Drug Carriers. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Despite many advances in gene therapy, the delivery of small interfering RNAs is still challenging. Erythrocytes are the most abundant cells in the human body, and their membrane possesses unique features. From them, erythrocytes membrane vesicles can be generated, employable as nano drug delivery system with prolonged blood residence and high biocompatibility.
Methods
Human erythrocyte ghosts were extruded in the presence of siRNA, and the objects were termed EMVs (erythrocyte membrane vesicles). An ultracentrifugation-based method was applied to select only the densest EMVs, ie, those containing siRNA. We evaluated their activity in vitro in B16F10 cells expressing fluorescent tdTomato and in vivo in B16F10 tumor-bearing mice after a single injection.
Results
The EMVs had a negative zeta potential, a particle size of 170 nm and excellent colloidal stability after one month of storage. With 0.3 nM siRNA, more than 75% gene knockdown was achieved in vitro, and 80% was achieved in vivo, at 2 days PI at 2.5 mg/kg. EMVs mostly accumulate around blood vessels in the lungs, brain and tumor. tdTomato fluorescence steadily decreased in tumor areas with higher EMVs concentration, which indicates efficient gene knockdown. Approximately 2% of the initial dose of EMVs was still present in the plasma after 2 days.
Conclusion
The entire production process of the purified siRNA-EMVs took approximately 4 hours. The erythrocyte marker CD47 offered protection against macrophage recognition in the spleen and in the blood. The excellent biocompatibility and pharmacokinetic properties of these materials make them promising platforms for future improvements, ie, active targeting and codelivery with conventional chemotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Nanostructured Materials, Jožef Stefan Institute, Ljubljana, 1000, Slovenia.
- Jožef Stefan International Postgraduate School, Ljubljana, 1000, Slovenia.
- Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia.
- Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, 1000, Slovenia.
- Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, 1000, Slovenia.
- Laboratory of Biophysics, Condensed Matter Physics Department, Jožef Stefan Institute, Ljubljana, 1000, Slovenia.
ORCID-Profile: Giulia Della Pelle, Bostjan Markelc, Mateja Erdani Kreft, Matic Kisovec
Zitieren
APA
Della Pelle, G., Markelc, B., Bozic, T., Šribar, J., Krizaj, I., Zagar Soderznik, K., Hudoklin, S., Kreft, M. E., Urbančič, I., Kisovec, M., Podobnik, M., & Kostevšek, N. (2025). Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency. International Journal of Nanomedicine, Volume 20, 3269-3301. https://doi.org/10.2147/ijn.s504644
Vancouver
Della Pelle G, Markelc B, Bozic T, Šribar J, Krizaj I, Zagar Soderznik K, et al. Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency. International Journal of Nanomedicine. 2025;Volume 20:3269-3301. doi:10.2147/ijn.s504644
BibTeX
@article{DellaPelle2025,
author = {Della Pelle, Giulia and Markelc, Bostjan and Bozic, Tim and Šribar, Jernej and Krizaj, Igor and Zagar Soderznik, Kristina and Hudoklin, Samo and Kreft, Mateja Erdani and Urbančič, Iztok and Kisovec, Matic and Podobnik, Marjetka and Kostevšek, Nina},
title = {Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency},
journal = {International Journal of Nanomedicine},
year = {2025},
volume = {Volume 20},
pages = {3269--3301},
doi = {10.2147/ijn.s504644}
}
EUVIMED